ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2073

Jumonji Domain Containing Protein 3 (JMJD3) As a Novel Epigenetic Mechanism of Fibroblast Activation By Regulation of Fra-2

Christina Bergmann1, Amelie Brandt2, Clara Dees3, Yun Zhang1, Neng-Yu Lin4, Chih-Wei Chen1, Tatjana Mallano5, Ruifang Liang3, Pui-See Kam6, Oliver Distler7, Georg Schett3 and Joerg HW Distler3, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine III, University of Erlangen-Nuremberg, Erlangen, Germany, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 4Friedrich Alexander University, Erlangen, Germany, 5Department of Internal Medicine III, Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, 6Internal Medicine III, University of Erlangen-Nuremberg, Erlangen, Germany, 7Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Histone Modification and fibrosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Session Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Prolonged endogenous activation of fibroblasts is a major hallmark of fibrosing disorders such as Systemic Sclerosis (SSc). It results in tissue fibrosis, organ failure and a high morbidity and mortality. Trimethylation of H3 at lysine residue K27 (H3K27me3) is an epigenetic mark that mediates gene repression. H3K27me3 was recently identified as an important negative regulator of fibroblast activation [1]. Demethylation of H3K27me3 is mediated by JMJD3. JMJD3 inhibitors are currently being tested as therapeutic strategies in malignant diseases. The aim of this study is to characterize the role of JMJD3 in fibroblast activation and to explore JMJD3 as a potential drug target in SSc.

Methods:   The expression of JMJD3 was analyzed by qPCR, IF and Western blot in patients with SSc, healthy controls and in experimental fibrosis. siRNA mediated knockdown and pharmacologic inhibition by GSKJ4 were used to target JMJD3. In vivo, the effects of JMJD3-inhibiton were analyzed in the mouse model of bleomycin-induced dermal fibrosis, in the model of Topoisomerase-I-induced (TopoI) fibrosis and in a mouse model with adenoviral overexpression of a constitutively active transforming growth factor beta (TGF-β) receptor type 1 (TBRact). Signaling pathways regulated by JMJD3 were analyzed in vitro and in vivo using qPCR, Western Blot and reporter assays.

Results: The expression of JMJD3 was increased in the skin of SSc patients as compared to healthy volunteers. Accumulation of JMJD3 was also observed in experimental models of SSc. TGF-β potently induced the expression of JMJD3 in vitro and in vivo. Pharmacologic inhibition and siRNA mediated knockdown of JMJD3 strongly upregulated the levels of H3K27me3 in vitro and in vivo. Inhibition of JMJD3 reverted the activated fibroblast phenotype in SSc fibroblasts and persistently decreased the expression of contractile fibers and of α-smooth muscle actin. Secretion of collagen was reduced upon inhibition of JMJD3. JMJD3- inhibition also resulted in a significant down-regulation of the profibrotic transcription factor Fra-2 in vitro and in vivo. Overexpression of Fra-2 in JMJD3-knockdown fibroblasts restored the profibrotic effect of JMJD3. In vivo, inhibition of JMJD3 ameliorated fibrosis in bleomycin-, TopoI- and TBRact-induced experimental fibrosiswith reduced dermal thickening, hydroxyproline content and myofibroblast differentiation. 

Conclusion: We present first evidence that histone methylation by JMJD3 contributes to the activated phenotype of SSc fibroblasts. JMJD3 is upregulated by TGF-β in SSc. Inhibition of JMJD3 prevents the aberrant collagen release and ameliorates the activated fibroblast phenotype in SSc fibroblasts. In vivo inhibition of JMJD3 has potent anti-fibrotic effects in several preclinical models of SSc. Reference: 1. Kramer, M., et al., Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis, 2013. 72(4): p. 614-20.  


Disclosure: C. Bergmann, None; A. Brandt, None; C. Dees, None; Y. Zhang, None; N. Y. Lin, None; C. W. Chen, None; T. Mallano, None; R. Liang, None; P. S. Kam, None; O. Distler, None; G. Schett, None; J. H. Distler, None.

To cite this abstract in AMA style:

Bergmann C, Brandt A, Dees C, Zhang Y, Lin NY, Chen CW, Mallano T, Liang R, Kam PS, Distler O, Schett G, Distler JH. Jumonji Domain Containing Protein 3 (JMJD3) As a Novel Epigenetic Mechanism of Fibroblast Activation By Regulation of Fra-2 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/jumonji-domain-containing-protein-3-jmjd3-as-a-novel-epigenetic-mechanism-of-fibroblast-activation-by-regulation-of-fra-2/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/jumonji-domain-containing-protein-3-jmjd3-as-a-novel-epigenetic-mechanism-of-fibroblast-activation-by-regulation-of-fra-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.